Business Wire

NEUSTAR

14.1.2020 09:02:07 CET | Business Wire | Press release

Share
Neustar Delivers UltraThreat Feeds for More Effective Data Security

Neustar® , Inc., a global information services company and leader in identity resolution, today announced the release of UltraThreat Feeds, a new service that provides its enterprise customers with access to real-time threat data to help them better identify cyber threats as they evolve. Designed by Neustar’s renowned security experts and leading academic researchers, the service – unique to Neustar – enables security and threat intelligence teams of all sizes to access threat feeds based on analysis and observations curated from Neustar’s expansive DNS, OneID and IP decisioning data.

Incorporating proprietary data derived from Neustar’s Security Portfolio & OneID identity resolution platform, UltraThreat Feeds can be ingested into a client’s existing platform to deliver superior threat data and provide valuable insights to unique and developing threats in near real-time.

“With the average cost of a data breach now at nearly $4 million, enterprises are investing significant resources into threat intelligence solutions to better defend themselves. A key change is enabling network and application security tools with improved real-time awareness of active threats,” said Rodney Joffe, security CTO, senior technologist and fellow at Neustar. “For example, SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls all require threat data to power their security functions to detect and block malicious actors. Neustar’s UltraThreat Feeds service delivers deep, rich threat data, giving users the power to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks.”

UltraThreat Feeds enable Neustar customers to identify:

  • Malicious Domain Generation Algorithms (“DGAs”) – When malicious actors register one of the thousands of domains that are created by the DGAs within their malware, and that then allow the actors to control infected hosts from their Command and Control Servers (C2).
  • Suspicious DNS Tunneling Attempts – When Domains leverage the DNS protocol to create a “tunnel” to exfiltrate data past customers’ security measures.
  • Newly Observed Domains – When a Domain with little or no history is suddenly active, which presents increased risk.
  • Domain Updates (Nameserver or Hosting IP Address) – When there are indications that a domain has been hijacked.
  • Domain Spoofing (Business Email Compromise) – When fake online personas trick victims into making fraudulent transactions by imitating or resembling legitimate domains.

Neustar’s UltraThreat Feeds service has an advantage over competitors, thanks to the availability of its own unique data assets, including DNS data exhaust collected from the more than 100 billion queries received from 30 globally distributed nodes every day and supplemented by the IP address intelligence and analytics processed across Neustar’s product suite. Combined with behavioural analysis and pattern-based research, this advantage enables Neustar to derive truly unique insights into malicious activity. With insight gained from Neustar’s globally distributed authoritative and recursive DNS network, Neustar OneID, IP Intelligence geolocation and risk data, UltraThreat Feeds can provide a proprietary view of global threats to help identify and stop bad traffic, both inbound and outbound.

"With increasing attacker sophistication, and renewed aggression from nation-state adversaries focused on corporate espionage, many organisations are trying to find out how to properly leverage these [threat intelligence] services to protect themselves," wrote Forrester analysts Josh Zelonis and Joseph Blankenship in the report, The Forrester Tech Tide™: Zero Trust Threat Detection And Response, Q1 2019.

For more technical details on Neustar UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultra-threat-detection-feeds .

-ENDS-

About Neustar

Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: www.home.neustar .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye